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Abstract: Today’s malaria control efforts are limited by
our incomplete understanding of the biology of Plasmo-
dium and of the complex relationships between human
populations and the multiple species of mosquito and
parasite. Research priorities include the development of in
vitro culture systems for the complete life cycle of P.
falciparum and P. vivax and the development of an
appropriate liver culture system to study hepatic stages.
In addition, genetic technologies for the manipulation of
Plasmodium need to be improved, the entire parasite
metabolome needs to be characterized to identify new
druggable targets, and improved information systems for
monitoring the changes in epidemiology, pathology, and
host-parasite-vector interactions as a result of intensified
control need to be established to bridge the gap between
bench, preclinical, clinical, and population-based sciences.
Introduction
The current malaria control effort has focused on developing
existing products and procedures (for example, drugs and the
distribution of bednets) to reduce malaria morbidity and mortality.
However, it is commonly accepted that eradication will not be
achieved with current tools. Thus, we must now accelerate the
development of a new generation of tools and knowledge aimed
specifically at malaria eradication. As we look towards this
ambitious goal, we must recognize that cutting-edge basic science,
novel research strategies, and creative multidisciplinary approach-
es all need to be mobilized to bridge the gap between bench,
preclinical, clinical, and population-based sciences. The malaria
science community is now at a turning point where major
advances are needed to move the field forward from control
towards the goal of global malaria eradication.
The malERA Consultative Group on Basic Science and
Enabling Technologies was convened to identify the major
knowledge gaps in basic science and to prioritize basic/
fundamental science approaches that might have an impact on
malaria eradication, particularly with respect to the design of
vaccines, drugs, and diagnostics. We recognize that there are likely
to be many more research questions that merit equal importance
in the broad field of malaria biology than we can cover in this
paper, but herein we highlight only those approaches that were
discussed by the consultative group and that may have a direct
bearing on malaria eradication.
Leading the charge are new molecular, chemical, immunolog-
ical, and epidemiological research tools that, whilst requiring
adaptation to malaria, have realizable rewards in the near future.
In particular, developments in systems biology, metabolomics,
glycomics, and lipid metabolism and new high-throughput
approaches involving chemical biology are likely to be of great
use in the field of malaria eradication. From these new avenues of
investigation, it is reasonable to expect advances in vaccine
development and the identification of novel drug targets.
Moreover, the interlacing of high-throughput molecular technol-
ogies with population studies will greatly facilitate the rational
application of interventions in diverse malaria-endemic environ-
ments and, we anticipate, will significantly increase our ability to
shed light on complex and heterogeneous host-parasite-vector
interactions.
At the basic science level, we specifically identified a deeper
understanding of the whole parasitic life cycle and the interaction
of the parasite with human and vector hosts at different stages as a
high priority. Such knowledge will augment our ability to evaluate
current and future interventions and allow us to determine the
potential action of drugs or vaccines across all parasite
developmental stages. In addition, a life cycle–based perspective
will provide insights into the transitions from one host to another
and highlight key points, triggers, decisions, and co-incident events
as the parasite moves from one life stage to the next that could
prove crucial in malaria eradication attempts.
Most importantly, the consultative group recognized that
multidisciplinary approaches will be required to exploit and apply
new knowledge and techniques in order to make significant and
novel gains in combating malaria. The malaria community needs
to involve experts who can bring technologies from other
seemingly distant areas of basic and applied research such as
physics, electronics, information technology, and engineering. By
defining desired outcomes, free from the constraints of precon-
ceived ideas based on current tools, an expansion of the malaria
research community skill base will create opportunities for lateral
thinking and bring with it new approaches not previously
considered.
This paper considers the key research priorities identified by the
malERA Consultative Group for basic sciences and enabling
technologies. Some of these key priorities have also been identified
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and discussed by the malERA Consultative Groups on vaccines,
drugs, and diagnoses and diagnostics [1–3].
Plasmodium In Vitro Culture Systems
The development of Plasmodium in vitro culture systems that
encompass the entire parasite life cycle of P. falciparum and P. vivax
is critical for efforts to develop new vaccines, drugs, diagnostic
tests, and challenge/test systems for clinical trials. The develop-
ment of such systems will require a sustained community-wide
collaborative effort and a long-term commitment. Specific stages
of the life cycle for human malaria parasites that remain key
priorities for in vitro culture development are sporogony, sustained
blood-stage culture for P. vivax, and the pre-erythrocytic liver stage.
In Vitro Culture of Mosquito Stages
To date, in vitro culture of mosquito stage parasites and, in
particular, in vitro development of sporozoites (sporogonic
development) has only been achieved for rodent malaria parasite
species; the reproduction of these achievements for P. falciparum—
and even more so P. vivax—has met with limited success [4–10].
The need for an effective, in vitro sporogonic culture system is
highlighted by the following example. In Brazil, the major local
vector Anopheles darlingi cannot be reared in the lab and, as in other
malaria endemic countries, the importation of laboratory colonies
of nonindigenous vector species is understandably prohibited.
Such a situation makes it difficult for endemic country scientists to
address one of the key issues pertaining to eradication—parasite
transmission through the mosquito. Moreover, despite several
attempts in the past, an appropriate Anopheles midgut cell line
model does not exist, which prevents an intimate analysis of
Plasmodium ookinete invasion of this mosquito tissue [11]. Thus, to
facilitate malaria control efforts in Brazil (and in other endemic
areas), it is essential that researchers work towards the develop-
ment of a simple, widely utilizable, and robust mosquito-free
(axenic) sporogonic culture system and an in vitro midgut cell
invasion assay for the major human malaria parasites.
P. vivax Blood-Stage Cultures
The availability of continuous in vitro blood-stage culture of P.
falciparum has revolutionized our understanding of the parasite
[12], but there is no analogous culture system for P. vivax research.
In part, this is because P. vivax has a predilection for reticulocytes,
a cell type that may need to be purified or generated from
hematopoietic stem cell progenitor cells—a process that has met
with only limited success [13–19]. The development of an efficient
inexpensive, automated P. vivax blood-stage culture system would
undoubtedly enhance the study of this parasite’s biology. It would
also enable in vitro drug susceptibility testing, the development of
growth inhibitory assays to test humoral immunity, and,
ultimately, the development of new genetic research methods.
Importantly, both the asexual and sexual stages would become
available for study, which would facilitate the generation of the
other stages of the life cycle using defined parasite strains, without
the requirement for primates.
Liver-Stage Cultures
Our current understanding of the biology of the parasite’s liver
stage (the hypnozoite stage) suggests this stage will be an important
target in efforts to eradicate malaria [20]. Specifically, hepatic
development occupies a critical position in mediating the
establishment of blood-stage infection and, consequently, the
transmission of malaria. Moreover, in the case of P. vivax, the
dormant hypnozoite stages remain in the liver for a variable and
protracted period before leading to relapse. Clearly, eradication of
P. vivax (and P. ovale) is unlikely to be attained without developing
effective hypnozoiticides.
The availability of a Plasmodium liver-stage model would allow
the investigation of the host factors that are involved in primary
and latent intrahepatic development and of the metabolic
pathways that regulate development of this parasitic stage. In
addition, the existence of such a model would allow the
development of much needed drug screens for this stage that
could, like the recently available drug screens for asexual blood-
stage infections [21–27], take advantage of the unprecedented
access to the three chemical compound libraries—GlaxoSmithK-
line’s Tres Cantos Antimalarial TCAMS dataset [24], the
Novartis-GNF Malaria Box Dataset, and the St. Jude Children’s
Hospital Malaria dataset [25]—that are hosted at ChEMBL-NTD
(www.ebi.ac.uk/chemblntd), an Open Access repository of prima-
ry screening and medicinal chemistry data.
Finally, with the resurgence in interest in genetically attenuated
or irradiated sporozoite-based, pre-erythrocytic vaccines [28,29], a
liver-stage model would permit investigation of the molecular basis
of their developmental arrest—an understanding that will be
critical in both the licensing of such vaccines and in ensuring that
breakthrough infections do not arise.
Thus, the development of in vitro systems to understand
hypnozoite biology as it relates to liver-stage biology is a clear
priority. However, the culture of parasites through the liver stage is
likely to be a significant challenge given the intractability of this
stage relative to other life stages. Such an endeavour will require a
highly collaborative and interdisciplinary approach that includes
specialists in the fields of hepatocyte and stem cell biology as well
as biomedical engineering. The development of hepatocytes that
maintain their polarity and normal trafficking properties is a
necessary step towards this kind of model, as is development of
primary or immortalized hepatocyte cultures with sufficient life
span to allow hypnozoite formation and survival [30–34]. Cell
lines that allow high infectivity and that can yield high parasite
numbers would be especially valuable for generating more useful
quantities of parasite material with which to work. Moreover, a
single hepatocyte line may not be amenable or useful to all the
different subdisciplines present in the malaria community. Some
may be appropriate for immunological studies, while others may
Summary Points
N Creative and collaborative multidisciplinary basic science
approaches are needed to address pressing questions
about the biology of Plasmodium
N The research paradigm needs to shift from a focus on
solely parasite or host to one that incorporates the triad
of parasite, mosquito, and human host and their
respective interactions
N Key research priorities include: the development of in
vitro culture systems for all life stages of P. falciparum
and P. vivax, in particular, hepatic stages; improved
genetic technologies for the manipulation of Plasmodi-
um; and systems-based approaches incorporating cut-
ting-edge technologies such as metabolomics
N Parasite, human, and vector research needs to be backed
up by in-depth population-based field studies
N Most importantly, eradication of malaria will require
bridging of the artificial gap between bench-based
research, preclinical research, clinical research, and
population-based science
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be suited to drug studies against primary or relapse infection from
hypnozoites [1,2]. Finally, it should be noted that the possibility of
using humanized mouse models engrafted with functional human
cells and tissues, including human hepatocytes or human
hematolymphoid cells, presents a unique in vivo approach that
could also facilitate our understanding of Plasmodium liver-stage
biology [35].
Primate Models of Disease
Not every aspect of parasite biology can be studied using in vitro
culture. In some cases, whole animal models will be needed. For
example, validated biomarkers for intrahepatic development and
markers of past infection that could help distinguish between new
infection and relapse will be important during elimination and can
only be identified in whole animal models [3,36]. Data from
primate studies could provide an interim platform for developing
novel diagnostics that could inform future work in parallel with in
vitro models [37–39]. Mechanisms to support cross-institute/
laboratory collaborations and access to the few centres with
expertise and resources in primate/malaria research would
facilitate and enhance a wide range of essential research.
Development of Genetic Tools for P. vivax and
Approaches for Systematic Mutagenesis in
Plasmodium
Major advances towards understanding fundamental aspects of
model organisms inherently follow technological innovations that
move fields in new directions. Thus, the ability to manipulate the
genomes of different Plasmodium species has revolutionized malaria
research. Nevertheless, we are still a long way from the systematic
use of reverse genetics seen in other model systems such as yeast.
For example, although the P. falciparum genome was completed
more than 5 years ago, as many as half of the annotated genes are
still listed as having a hypothetical or unknown function; around
90% of the genes have little biological evidence for function.
Furthermore, little is being done currently to coordinate the study
of individual genes or gene families, with the exception of recent
efforts to systematically define the function of proteins involved in
erythrocyte remodeling and export [40].
Despite many recent improvements to genetic technologies in
Plasmodium, many roadblocks that prevent scale-up of genetic
manipulation and functional analysis of essential genes need to be
overcome [41–44]. These roadblocks include the low frequency of
homologous recombination in Plasmodium, difficulties associated
with the manipulation of large fragments of AT-rich and repetitive
genomic DNA, and the lack of robust and scalable systems for
conditional gene expression. In addition, there are no practical
strategies for achieving saturation mutagenesis. Technologies to
tackle some of these roadblocks are available for other organisms
[45,46] and need to be introduced to the malaria research agenda.
If these technical limitations can be overcome, systematic
mutagenesis on a genome-wide scale will allow us to distinguish
essential from redundant metabolic pathways and will be critical to
obtaining a comprehensive picture of the stage-specific biology of
the parasite that could be targeted with drugs or vaccines. Stable,
conditional knock-out approaches for genes that are essential in
one life stage but not in another would also identify potential drug
targets. Improved genetic technologies will also enable the
systematic production of large-scale repositories of gene knock-
out or epitope-tagged versions for every plasmodial gene. Such
community resources would avoid duplication and benefit from
the economy of scale. More importantly, easy access to large
numbers of mutants would inspire new experimental approaches,
as they have in the yeast field [47–49], and widen access to genetic
technology.
Finally, the recent completion of several parasite and mosquito
genomes [50–54] and new insights into the contribution of human
and mosquito host genotype to transmission have radically
changed how researchers approach malaria. This information,
together with an internationally accessible repository of transgenic
lines for every Plasmodium gene, will change the way that the
research community approaches the most basic and relevant
questions related to Plasmodium biology (of all species) and
interactions of the various Plasmodium species with their hosts.
Metabolomics
As with genomic innovations, new technological platforms that
permit the deep characterization of the metabolome (complete set
of small-molecule metabolites) of Plasmodium will identify new
potentially druggable targets [55,56]. Indeed, analysis of the
parasite’s metabolome is already revealing profound new insights
into parasite biology that were not amenable to or that were
missed by genomic approaches [57–59]. For metabolites that are
readily identifiable, differences among parasite strains, under
varying drug conditions, or in mutant backgrounds will enhance
understanding of the known metabolic pathways present in
Plasmodium spp. However, many of the measurable compounds
are likely to derive from previously undetected novel metabolites
(including the products of poorly understood lipid and carbohy-
drate metabolism). The identification of these compounds could
yield key insights for the development of new antimalarial drugs or
the control of drug resistance. Moreover, the identification of the
metabolic similarities between different parasite stages could
provide new approaches to the development of drugs with
potential to kill the parasites at many points in their life cycle,
possibly in both the human host and the mosquito vector [58–61].
Metabolomic approaches should also enable identification of
metabolic differences between, for example, patients who are
asymptomatic and those with advanced stage cerebral malaria (or
other severe syndromes). Metabolomic studies of such samples
may not only provide information about the state of the host, but
also about the interaction between the host and the parasite. The
Consultative Group felt that such studies, which bring together
bench scientists and field clinicians, should be encouraged as the
true picture of the diversity of metabolic effects can only be fully
appreciated from field-derived samples. Finally, the group noted
that the application of metabolomic technology will be particularly
powerful in unraveling the biochemical strategies of parasites with
no or poor genomic resources such as P. ovale or P. malariae.
The Importance of Relating Molecular Science to
Field Science
The emergence of artemisinin resistance [62,63] and changes in
the interrelationships of humans, mosquitoes, and parasites as
elimination proceeds will produce unexpected new challenges.
The Consultative Group, therefore, considered it a priority to
establish information systems for monitoring the changes in
epidemiology, pathology, and host-parasite-vector interactions
that result from intensified control and burgeoning elimination
efforts so that basic research can react in a timely manner to
changing circumstances (see also [36,64]).
Indeed, a core theme in our discussions was that, throughout
the eradication era, basic science and multidisciplinary approaches
must be seen as integral components of a Malaria Eradication
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Research Agenda that are valuable even in the absence of clear
field application because one can never predict the impact of novel
insights. Enabling technologies cut across many themes in this
agenda (see Box 1), and the application of basic science in the field
is especially important. For example, genomic, proteomic, and
high-throughput immunological methods can now be applied to
population studies, greatly increasing their ability to shed light on
complex host-parasite-vector interactions [65,66].
Human Host Factors and Improving
Epidemiological Models
No campaign for the control or elimination of malaria can
proceed without a detailed appreciation of the epidemiology of the
disease and of host-parasite-vector interactions. As increasing parts
of the world move towards elimination, a deeper understanding of
the basic science of host-parasite-vector population interactions in
disease transmission and of the changes in these interactions that
result from intensified control and elimination efforts will be
increasingly important [64].
For example, mixed species and strain infections are common in
natural malaria infections in both human and vector hosts [67,68].
Application of next generation high-throughput sequencing and
genotyping of mixed infections in both obligate hosts will help to
identify important target genes and phenotypes and will provide
insights into whether and how parasites impact each other’s
behaviour in the context of the human host and transmission
through the vector host that will be important as elimination
proceeds.
Similarly, a better understanding of the human response to
malaria will be increasingly important as elimination proceeds.
Despite many decades of studies on immune responses to
malaria, there is still no consensus on an immune correlate of
protection [69,70]. Well designed, longitudinal studies in which
the exposure to malaria and protection against uncomplicated or
severe malaria are reliably assessed are required to remedy this
shortcoming. Other modern technologies that offer new ap-
proaches to understanding the potential mechanism of action of
compounds or antibodies on malaria will also need to be fully
introduced into ongoing and planned longitudinal studies of
human populations.
Vector-Host-Parasite Interactions
Strategies aimed at decreasing mosquito life span are predicted
to impact upon transmission (see also [2,71]). Research that
investigates the parasite stages that develop within the mosquito
and their transmission through the vector is likely to be of great
use, therefore, in malaria control and eradication. Focused
research efforts designed to understand the epidemiology of the
gametocyte and how it varies with species, with host, and with the
environment are required. Insights arising from such research will
be critical for determining the driving factors for new human and
mosquito infections, and manipulation of these factors will open
up new avenues for targeting the key parasite regulatory switches
that occur when a parasite undergoes a transition event.
Importantly, however, such a focus on transmission need not
necessarily be aimed at finding a magic bullet—a compound that
can work against all parasite stages in all hosts. Instead, there will
be significant utility in developing several inhibitors with similar
pharmacokinetic and pharmacodynamic profiles that affect
different metabolic pathways and stages in a combined drug
treatment regimen. For now, the absence of compounds that
preferentially affect gametocytogenesis, gamete-ookinete, or ooki-
nete-oocyst transition as well as the lack of understanding of the
mechanism of action for those very few currently available
compounds highlights the need for renewed efforts in this area
[72].
Box 1. Enabling Technologies: Cross-Cutting
Themes
N Collaborative approaches that bridge the gap between
basic laboratory, preclinical, and clinical/population-
based sciences
N Complete P. falciparum and P. vivax in vitro culture
systems for the discovery of new targets, the character-
ization of the entire metabolome, and the evaluation of
current and next generation interventions
N Development and wide distribution of several viable,
easy to maintain polarized hepatocyte cell lines that
support enhanced (.2% infection) P. falciparum and P.
vivax intrahepatic development, and that are amenable
to metabolomic, proteomic, glycomic and immunolog-
ical studies, and the evaluation of new interventions
N Scalable genetic technologies that enable a shared
resource containing genome-wide sets of genetically
modified (knock-out/tagged) parasite lines (for P. falci-
parum, P. vivax, and the murine malaria parasites) to be
maintained
N Novel classes of molecules that can function as chemical
tools for probing the function of genes at transition
stages; most especially the commitment to dormant liver
stages and gametocytogenesis
Box 2. Summary of the Research and
Development Agenda for Basic Science
Research
N A research paradigm shift away from the ‘‘parasite-first’’
approach to an examination of what the human and
mosquito host cells provide to the developing parasite is
needed to complement on-going approaches
N A new approach is needed to support collaborative and
truly cross-disciplinary arrangements among scientists to
bridge the gap between basic laboratory and clinical/
population-based sciences and to meet the scientific
benchmarks outlined by malERA
N Desired target product profiles need to be defined
without preferred technological approaches being sug-
gested to create opportunities for lateral thinking by
experts bringing new approaches from different fields
N Careful evaluation and appropriate use of today’s
technologies from the physical, chemical, and biomed-
ical engineering sciences is needed to improve the
molecular understanding of parasite developmental
biology and of the mammalian host-parasite-vector
interactions
N Mechanism of action studies for drugs and vaccines in
the current pipeline are also needed to inform future
strategies for the development of the next generation of
interventions and therapeutics
N The study of human host and vector factors in large-
scale, long-term population-based field studies and the
use of appropriate technologies in translation applica-
tions is also essential.
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Concluding Remarks
From our discussions, we propose a basic science research and
development agenda for malaria eradication (Box 2) that will
hopefully yield new interventions that are not hindered by the
current drug resistance status of the parasites or by changes in
environmental and host factors.
Central to this agenda is our contention that the establishment
of a spectrum of creative and novel eradication interventions will
require a strong commitment to collaborative work, wherein
interdisciplinary teams of basic scientists, both within and outside
of the malaria field, are organized and tasked with achieving well-
defined research milestones. It is crucial that scientists have the
possibility and flexibility to move between the field and the bench
for collaborative translational research, an emerging specialty in its
own right. Once individuals embrace the diversity of expertise
necessary in the malaria research of the future, the promotion of a
greater collaborative culture will inevitably make translation from
bench to bedside more readily achievable. However, the 10–15-
year timeline of translation from the bench to practical use in the
clinic or field remains a significant barrier to progress that has to
be recognized. Finally and importantly, our challenge to basic and
applied scientists to engage in stronger partnership across projects
and disciplines overrides some of the current guiding principles in
science such as institutional and individual performance assess-
ments and impact factors. These criteria may have helped to shape
individual careers but they have rarely helped to answer major
public health questions and should not be allowed to interfere with
progress towards malaria eradication.
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